Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.31 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | CCR3 | P51677 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859660 | 0.82 | PLG (0.40) | POLBCCR3 | |
| SCHEMBL1368801 | 0.81 | POLB (0.51) | CA1CA2CA4CA9POLB | |
| SCHEMBL14986325 | 0.81 | POLB (0.51) | CA1CA2CA4CA9POLB | |
| SCHEMBL11386097 | 0.81 | POLB (0.51) | CA1CA2CA4CA9POLB | |
| SCHEMBL4578016 | 0.80 | CA2 (0.42) | CA1CA2CA4CA9HRH3 | |
| Tert-Butyl Formate SCHEMBL27914286 | 0.78 | CA1 (0.41) | ADRB1CA1CA2CA4CA9 | |
| SCHEMBL14025126 | 0.77 | SMN1; SMN2 (0.46) | CA1CA2CA4CA9CCR3 | |
| SCHEMBL18852037 | 0.77 | SIRT6 (0.47) | HRH3POLB | |
| SCHEMBL22850050 | 0.74 | — | — | |
| SCHEMBL18577258 | 0.73 | LSS (0.44) | POLBCHIT1CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | ADRB1 53/4885CA1 3692/4885CA2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.